NCT01188252已完成1 期
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 112
- 主要终点
- Safety: Frequency of adverse events
研究概览
简要总结
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY1000394 given in an intermittent 3 days on / 4 days off schedule to patients with advanced malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- •Life expectancy of at least 12 weeks
- •Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable
- •At least 1 tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1
- •Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements to be conducted within 14 days prior to the first dose of study drug
排除标准
- •History of cardiac disease: congestive heart failure > NYHA Class II, unstable angina (anginal symptoms at rest), any episodes of angina or history of myocardial infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), previous venous or arterial thrombotic events, pulmonary embolism
- •Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C(3)
- •History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
- •Active clinically serious infections of CTCAE > Grade 2 (CTCAE v4.02)
- •Symptomatic metastatic brain or meningeal tumors unless the subject is > 3 months from definitive therapy, has no evidence of tumor growth on an imaging study within 4 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry. Subjects must not be on acute steroid therapy or taper off steroid therapy (chronic steroid therapy is acceptable provided that the dose is stable for 4 weeks prior to study entry and following screening CT / MRI scan). Subjects with neurological symptoms should undergo a CT / MRI scan of the brain to exclude new or progressive brain metastases. Spinal cord metastasis is acceptable
- •Seizure disorder requiring therapy (such as steroids or anti-epileptics)
- •History of organ allograft
- •Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE > Grade 2 within 4 weeks prior to prior to the first dose of study drug
研究组 & 干预措施
Roniciclib
Experimental
干预措施: Roniciclib (BAY1000394) (Drug)
结局指标
主要结局
Safety: Frequency of adverse events
时间窗: Up to 3 years or longer if indicated
Maximum tolerated dose: Measured by adverse event profile
时间窗: Up to 3 years or longer if indicated
Pharmacokinetics: Plasma concentrations of BAY1000394 will be measured. The following parameters will be calculated: Cmax, tmax, AUC(0-tn), AUC, and half-life.
时间窗: Approximately 6 weeks
次要结局
- Assessment of intracellular biomarkers of apoptosis (for example activated caspase 3, annexin V, expression of MCL 1 for patients with chronic lymphocytic leucemia only(Approximately 6 weeks)
- Biomarkers evaluation: analysis of apoptosis marker CK18/M30 and total soluble cytokeratin CK18/M65(Up to 3 years or longer if indicated)
- Tumor response evaluation based on RECIST 1.1 (solid tumors) or response based on the pertinent guidelines (malignant lymphoma, chronic lymphocytic leukemia) every 2 cycles(Up to 3 years or longer if indicated)
- Assessment of expression (IHC) and amplification status (FISH) of markers related to cell proliferation and the cell cycle in Paraffin-embedded archival tumor samples. These will include, but may not be limited to Cyclin E, Cyclin D, p21, and Ki67(From archival tumor blocks)
- Functional testing of peripheral leucocytes, for example induction of cytokine synthesis(Approximately 6 weeks)
研究者
相似试验
终止
1 期
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid TumorsNeoplasmsNCT01065623Bayer2
已完成
1 期
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced CancerNeoplasmsNCT01938638Bayer80
已完成
1 期
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)HypophosphatasiaNCT04980248Alexion Pharmaceuticals, Inc.15
终止
1 期
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)Medical OncologyNCT02368951Bayer20
Unknown
1 期
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid TumorsSolid TumorNCT05360368Shanghai Henlius Biotech24